Hello, everyone, and how are you today? We are doing just fine, thank you, helped along by a shiny sun enveloping the otherwise chilly Pharmalot campus. A few cups of stimulation can also be useful, we are the first to confess. Meanwhile, we are as busy as ever, foraging for interesting items. On that note, here are a few tidbits to help you on your own journey. We hope all goes well today and that you conquer the world. And as always, do keep in touch. We appreciate your insights …

A Food and Drug Administration advisory panel overwhelmingly voted to approve an Amgen (AMGN) osteoporosis treatment for postmenopausal women at high risk for fracture, Reuters reports. The panel voted 16-1 in favor of the monthly injection developed jointly with UCB. The drug, Evenity, helps reduce the risk of fracture by increasing bone formation and inhibiting breakdown of bone minerals. However, the panel raised concerns about cardiovascular safety risks linked to the drug, which FDA staff reviewers had cited as the main reason for convening the panel meeting.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy